ALK and non-small cell lung carcinoma: A fast-tracked FDA approval was given to crizotinib, a potent c-Met/ALK dual inhibitor that demonstrated significant efficacy for a subset of NSCLC patients with an EML4-ALK fusion gene [16,17].